131918-61-1 Usage
Description
Different sources of media describe the Description of 131918-61-1 differently. You can refer to the following data:
1. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
2. Paricalcitol was launched as Zemplar in the US for the prevention and
treatment of secondary hyperthyroidism associated with chronic renal failure.
Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue
in which the ring A exocyclic methylene group, typical of all vitamin D
systems, has been replaced by two hydrogen atoms. Paricalcitol is the first
vitamin D analogue marketed for this indication. In patients with chronic renal
failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH)
without a significant difference in the incidence rate for hypercalcemia or
hyperphosphatemia when compared with placebo.
Chemical Properties
White Solid
Originator
Abbott (US)
Uses
Different sources of media describe the Uses of 131918-61-1 differently. You can refer to the following data:
1. Synthetic analog of vitamin D. Antihyperparathyroid.
2. Antihyperparathyriod
3. 1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
Brand name
Zemplar (Abbott).
Clinical Use
Vitamin D analogue:
Treatment and prevention of secondary
hyperparathyroidism associated with chronic renal
failure
Drug interactions
Potentially hazardous interactions with other drugs
None known
Metabolism
Extensively metabolised via hepatic and non-hepatic
pathways to form two relatively inactive metabolites.
After oral administration of 3
H-paricalcitol, only about
2% of the dose was eliminated unchanged in the faeces,
and no parent drug found in the urine. Approximately
70% of the radioactivity was eliminated in the faeces and
18% was recovered in the urine. Most of the systemic
exposure was from the parent drug.
Check Digit Verification of cas no
The CAS Registry Mumber 131918-61-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,9,1 and 8 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 131918-61:
(8*1)+(7*3)+(6*1)+(5*9)+(4*1)+(3*8)+(2*6)+(1*1)=121
121 % 10 = 1
So 131918-61-1 is a valid CAS Registry Number.
InChI:InChI=1/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
131918-61-1Relevant articles and documents
Synthesis of paricalcitol: A novel strategy combining chemical and microbial transformations
Luo,Jiang,Song,Fang,Lu
, p. 323 - 327 (2017)
A novel strategy was developed for the preparation of paricalcitol (1α,25-dihydroxy-19-norvitamin D2) via seven-step chemical transformation and one-step microbial transformation. Using vitamin D2 as a starting material, 1α- and 25-hydroxyl groups of paricalcitol were introduced by Pseudonocardia autotrophica CGMCC5098 at the late stage of the synthesis, allowing us to avoid harsh reaction conditions and tedious steps. The overall yield of paricalcitol was 0.75%.
Preparation method of paricalcitol isomer impurity PY5
-
Paragraph 0041-0047, (2019/10/23)
The invention discloses a preparation method of paricalcitol isomer impurity PY5. The preparation method comprises the following steps: taking (1R, 3aR, 7aR)-1-((2R,5R,E)-5,6-dimethyl heptyl-3-alkene-2-yl)-7a-methyl octahydro-4H-indole-4-ketone as a start
Preparation method for paricalcitol
-
, (2018/04/01)
The invention discloses a preparation method for paricalcitol. The preparation method comprises the following steps: (1) subjecting a compound 1 to a hydrolysis reaction so as to prepare a compound 2;(2) subjecting the compound 2 to oxidation with Dess-Martin periodinane so as to prepare a compound 3; (3) subjecting the compound 3 to a reaction with a compound 4 so as to prepare a compound 5; and(4) subjecting the compound 5 to hydrolysis so as to prepare a crude paricalcitol product. Accordinccording to the method of the invention, the content of an epimer impurity B in the crude paricalcitol product is reduced from the source by selecting appropriate reaction conditions, and subsequent purification steps for paricalcitol are simplified; and the preparation method has high yield and little impurities, and is more suitable for large-scale industrial production.